Location History:
- Mt. Pleasant, SC (US) (1986)
- Bethesda, MD (US) (1997 - 2024)
Company Filing History:
12 out of 29 
3 out of 3 
2 out of 3 Years Active: 1986-2025
Title: The Innovative Contributions of Inventor Kwong Y Tsang
Introduction
Kwong Y Tsang, an accomplished inventor based in Bethesda, MD, has made significant strides in the field of immunology with his 17 patents. His work focuses primarily on innovative therapeutic methods utilizing monoclonal antibodies, specifically targeting regulatory T cells (Treg cells) for cancer treatment.
Latest Patents
Kwong Y Tsang's recent patents highlight his expertise in immunotherapy. One of his notable inventions is a method and composition for targeting Treg cells, wherein the antibody NEO-201 is detailed for its ability to bind to these cells. This innovation presents the potential for isolating, detecting, or purifying active Treg cells and includes therapeutic methods that use NEO-201, sometimes in conjunction with another agent.
Additionally, Tsang's patent on a monoclonal antibody, NEO-201, showcases its effectiveness against various human carcinomas, including those affecting the colon, pancreas, and breast. Functional assays confirm that NEO-201 can mediate both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against tumor cells. His research indicates that treatment with NEO-201 can significantly hinder the growth of human pancreatic xenograft tumors.
Career Highlights
Throughout his career, Kwong Y Tsang has been affiliated with companies like Precision Biologics, Inc. and International Bioimmune Systems, Inc., where he utilized his expertise to advance cancer treatment technologies. His contributions in these organizations speak to his commitment to innovation in the biomedical field.
Collaborations
In his journey as an inventor, Tsang has collaborated with other notable professionals like Myron Arlen and J Andrew Bristol. These partnerships have further enhanced the development and applicability of his patents, especially in targeted cancer therapies.
Conclusion
Kwong Y Tsang exemplifies the traits of a leading innovator in the scientific community. His continued focus on developing advanced therapeutic methods demonstrates his commitment to combating cancers through cutting-edge antibody research. The impact of his inventions, particularly the NEO-201 antibody, holds immense promise for improving treatment outcomes for patients affected by various carcinomas.